SCOTTSDALE, Ariz., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced revenues of approximately $174.0 million for the three months ended June 30, 2010, compared to revenues of approximately $141.2 million for the three months ended June 30, 2009, which represents an increase of approximately $32.8 million, or approximately 23.2%. This increase is due primarily to the strength of SOLODYN®, ZIANA® and the aesthetic franchises including RESTYLANE® and DYSPORT®, partially offset by decreased sales of LOPROX® due to generic competition.
